Vol. 3 No. 1 (2023)
Reimbursement Recommendations

Tebentafusp (Kimmtrak)

decorative image

Published January 20, 2023

Key Messages

  • CADTH recommends that Kimmtrak be reimbursed by public drug plans for the treatment of unresectable or metastatic uveal melanoma (mUM) if certain conditions are met.
  • Kimmtrak should only be covered to treat adults with uveal melanoma whose cancer cannot be removed by surgery or has spread and who have tested positive for the HLA-A*02:01 gene. Patients receiving Kimmtrak should be in relatively good health (i.e., have a good performance status, as determined by a specialist). Cancer in central nervous system should either be controlled or that there be no spread of cancer to the brain at all.
  • Kimmtrak should only be reimbursed if prescribed by a specialist with expertise in managing uveal melanoma and cytokine release syndrome, and the cost of Kimmtrak is reduced.